Application and validation of a coaxial liquid core waveguide fluorescence detector for the permeation analysis of desmopressin acetate

Kottke, D; Burckhardt, Bjoern B.; Breitkreutz, Jörg; Fischer, Björn

doi:10.1016/j.talanta.2021.122145

Cited by 8 publications

(7 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2.9.40 was calculated. An HPLC method, which was validated in a previous study ( Kottke et al, 2021 ), was used to determine desmopressin concentration. An HPLC (Dionex, Sunnyvale, California) using an EC 125/4 Nucleosil 120–3 C18 column (Macherey Nagel, Düren, Germany) was coupled to a self-constructed, highly sensitive, coaxial liquid-core waveguide fluorescence detector.…”

Section: Methodsmentioning

confidence: 99%

“…A self-constructed, highly sensitive, coaxial liquid-core waveguide fluorescence detector ( Kottke et al, 2021 ) was used to quantify the amount of desmopressin that permeated within one hour. Because the detector system allows reliable quantification of desmopressin concentrations down to 10 ng/mL, this system has been successfully applied as an alternative to the more commonly used liquid chromatography-tandem mass spectrometry (LC-MS/MS) detection method for permeation studies ( Majid et al, 2021 ).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Development and evaluation of a composite dosage form containing desmopressin acetate for buccal administration

Kottke

Burckhardt

Knaab

et al. 2021

International Journal of Pharmaceutics: X

Self Cite

View full text Add to dashboard Cite

Desmopressin acetate (DDAVP) is an oligopeptide indicated for the treatment of primary nocturnal enuresis, for example. The poor oral bioavailability of DDAVP accelerated a shift to alternative routes of administration like nasal and oromucosal, whereby nasal administration results in high fluctuations increasing the risk of undesirable side effects. Aim of the study was to use a new composite dosage form (solid matrix attached to a bilayer mucoadhesive film) to make DDAVP available via oromucosal route, reducing the risk of undesirable side effects through precise dosing. DDAVP was incorporated into a solid matrix in the form of a minitablet, and both direct tableting (AV > 30) and granulation followed by tableting (AV = 17.86) were compared. Minitablets with content uniformity could only be obtained by granulation and loss supplementation (AV = 11.27) with immediate drug release (>80% after 7–8 min) and rapid disintegration (<49 s). Permeation studies were performed with a clinically relevant dose (200 μg) in a time interval of up to one hour, resulting in apparent permeation coefficients of 4.90 × 10 −6 cm/s (minitablet) and 2.04 × 10 −6 cm/s (composite). Comparable fluctuations showed no inferiority of composite and minitablet regarding dosing accuracy. Thus, a step towards controlled and dose-accurate transmucosal delivery of systemically active DDAVP could be achieved.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Development and evaluation of a composite dosage form containing desmopressin acetate for buccal administration

Kottke

Burckhardt

Knaab

et al. 2021

International Journal of Pharmaceutics: X

Self Cite

View full text Add to dashboard Cite

show abstract

“…A modified detection system compared to the detection system used in this work with a charged-coupled device including optical fibers and a liquid-core waveguide was utilized by Kottke et al to detect low concentrations of desmopressin during permeation studies. However, they used fluorescence measurements to be able to detect 9.5 ng/mL of desmopressin, a method that was tenfold more sensitive in comparison with reference HPLC detection systems [ 21 ]. In this study, drug preparations of three different APIs were analyzed with substantially different dosage ranges.…”

Section: Introductionmentioning

confidence: 99%

Embedding a Sensitive Liquid-Core Waveguide UV Detector into an HPLC-UV System for Simultaneous Quantification of Differently Dosed Active Ingredients during Drug Release

et al. 2022

Self Cite

View full text Add to dashboard Cite

Individual dosing of pharmaceutics and personalized medicine have become important with regard to therapeutic safety. Dose adjustments, biorelevant drug release and combination of multiple active substances in one dosage form for the reduction in polymedication are essential aspects that increase the safety and acceptance of the patient’s pharmacotherapy. Therefore, not only innovative drug products but also new analytical methods are needed during the drug development phase and for quality control that can simultaneously determine different active ingredients and cover wide concentration ranges. We investigated a liquid-core waveguide UV absorbance flow cell detector coupled to an existing HPLC-UV system. A Teflon AF 2400 capillary tubing of 20 cm length was connected in series to the HPLC flow line and enabled a lower limit of quantification of 1 ng/mL pramipexole (increase in sensitivity by 20 compared to common 0.9 cm flow cells). This allowed the low-concentration of pramipexole and the higher concentrations of levodopa and benserazide occurring during drug release to be determined in a single chromatographic run within 22.5 min.

show abstract

“…Liquid-core optofluidic configurations, as one of the optofluidic systems, typically consist of an aqueous-core layer and a solid cladding layer 1 . The unique structure of these platforms enable a single miniaturized device to realize liquid sample holding and optical guiding functions simultaneously for applications such as fluorescence-based biosensors 2,3 , absorption spectroscopy 4,5 , and medical studies 6,7 . To achieve an efficient light guiding function, the refractive index of the core layer should be higher than the cladding layer to fulfill total internal reflection (TIR 8 ).…”

Section: Introductionmentioning

confidence: 99%

On-Demand Fully-Enclosed Superhydrophobic-Optofluidic Device Enabled by High Precision Microstereolithography

Chang

Bao

Waitkus

et al. 2022

Preprint

View full text Add to dashboard Cite

Superhydrophobic surface-based optofluidics have been introduced to biosensors and unconventional optics with unique advantages such as low light loss and power consumption. However, most of these platforms were made with planar-like micro- and nano-structures, which may cause bonding issues and resulting in significant waveguide loss. Here, we introduce a fully-enclosed superhydrophobic-based optofluidics system, enabled by a one-step high precision microstereolithography procedure. Various micro-structured cladding designs with a feature size down to 100 μm were studied and a “T-type” overhang design exhibits the lowest optical loss, regardless of the excitation wavelength. Surprisingly, the optical loss of superhydrophobic-based optofluidics is not solely decided by the solid area fraction at the solid/water/air interface, but also the cross-section shape and the effective cladding layer composition. We show that this fully-enclosed optofluidic system can be used for CRISPR-labeled quantum dot quantification, intended for in vitro and in vivo CRISPR therapeutics.

show abstract

Application and validation of a coaxial liquid core waveguide fluorescence detector for the permeation analysis of desmopressin acetate

Cited by 8 publications

References 54 publications

Development and evaluation of a composite dosage form containing desmopressin acetate for buccal administration

Development and evaluation of a composite dosage form containing desmopressin acetate for buccal administration

Embedding a Sensitive Liquid-Core Waveguide UV Detector into an HPLC-UV System for Simultaneous Quantification of Differently Dosed Active Ingredients during Drug Release

On-Demand Fully-Enclosed Superhydrophobic-Optofluidic Device Enabled by High Precision Microstereolithography

Contact Info

Product

Resources

About